Promising pre-clinical data on TG1050 presented at EASL 2013

Pre-clinical data on TG1050 was presented at EASL 2013, which took place in Amsterdam

Promising pre-clinical data on the novel immunotherapeutic TG1050 to treat chronic hepatitis B infection was presented at the European Association for the Study of the Liver Conference (EASL).
That is according to a statement from the biopharmaceutical organisation Transgene, which develops targeted immunotherapy products to treat those with cancer and chronic infectious diseases.
TG1050 is based on a non-replicative Adenovirus 5 vector that encodes three hepatitis B virus (HBV) antigens or related domains.
Chief executive of Transgene, Phillippe Archinard, revealed he was excited that TG1050 was chosen to be presented at this year's EASL in Amsterdam.
He said: "We hope that this presentation will trigger interest in the scientific community as well as discussions with potential partners."
Indeed, Mr Archinard hopes to begin the first-in-human/phase 1 clinical trial next year.
The presentation provided the most up-to-date data that demonstrated the capacity of TG1050 to induce long-lasting HBV-specific memory T cells.